Belite Bio, INC (BLTE) — SEC Filings

Q: What are the key financial highlights for Belite Bio, INC?

Key financial highlights for Belite Bio, INC are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Belite Bio, INC?

Key executives at Belite Bio, INC are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Belite Bio, INC stock?

Risk factors for Belite Bio, INC (BLTE) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Belite Bio, INC?

Forward-looking statements and predictions from Belite Bio, INC are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Belite Bio, INC. Recent 6-K filing on Mar 31, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Belite Bio, INC on SEC EDGAR

Overview

Belite Bio, INC (BLTE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 20-F filed on Mar 31, 2026: Belite Bio, Inc. (BLTE) reported no revenue for the fiscal year ended December 31, 2025, consistent with its pre-commercial stage as a clinical-stage biopharmaceutical company. The company continues to incur net cash outflow from operating activities, indicating ongoing significant investment in res

Sentiment Summary

Across 27 filings, the sentiment breakdown is: 3 bullish, 1 bearish, 23 neutral. The dominant filing sentiment for Belite Bio, INC is neutral.

Filing Type Overview

Belite Bio, INC (BLTE) has filed 23 6-K, 3 20-F, 1 SC 13G with the SEC between Feb 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (27)

6-K Filing — 6-K · Mar 31, 2026
Belite Bio's Future Hinges on Tinlarebant as Cash Outflows Continue — 20-F · Mar 31, 2026 Risk: high
Belite Bio, Inc. (BLTE) reported no revenue for the fiscal year ended December 31, 2025, consistent with its pre-commercial stage as a clinical-stage biopharmac
6-K Filing — 6-K · Dec 2, 2025
Belite Bio's Tinlarebant Shows Promise in Stargardt Disease Trial — 6-K · Dec 1, 2025 Risk: medium
On December 1, 2025, Belite Bio, Inc. announced positive topline results from its pivotal global Phase 3 DRAGON trial for tinlarebant in adolescents with Starga
6-K Filing — 6-K · Nov 10, 2025
Belite Bio Secures PIPE Financing — 6-K · Sep 8, 2025 Risk: medium
On September 8, 2025, Belite Bio, Inc. announced a private placement in public equity (PIPE) financing. The company entered into Securities Purchase Agreements
Belite Bio Reports Q2 2025 Financials and Corporate Update — 6-K · Aug 11, 2025 Risk: low
Belite Bio, Inc. announced its second quarter 2025 financial results and provided a corporate update via a press release on August 11, 2025. The company is a fo
Belite Bio Announces Registered Direct Offering — 6-K · Aug 7, 2025 Risk: medium
On August 6, 2025, Belite Bio, Inc. entered into a securities purchase agreement with an institutional investor for a registered direct offering. The offering i
Belite Bio Completes Enrollment in Geographic Atrophy Trial — 6-K · Jul 2, 2025 Risk: medium
On July 2, 2025, Belite Bio, Inc. announced the completion of patient enrollment in its pivotal global Phase 3 PHOENIX trial. This trial is evaluating the oral
Belite Bio's Tinlarebant Gets FDA Breakthrough Therapy Designation — 6-K · May 21, 2025 Risk: medium
On May 21, 2025, Belite Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its drug candidate,
Belite Bio Reports Q1 2025 Results and Corporate Update — 6-K · May 14, 2025 Risk: low
Belite Bio, Inc. announced its first-quarter 2025 financial results and provided a corporate update via a press release on May 13, 2025. The company is a foreig
Belite Bio Shareholders Approve All Proposed Resolutions — 6-K · Apr 15, 2025 Risk: low
Belite Bio, Inc. announced that all proposed resolutions from its March 18, 2025 Notice of Annual General Meeting were passed at the shareholder meeting held on
Belite Bio Changes Auditors to Deloitte & Touche — 6-K · Mar 28, 2025 Risk: low
Belite Bio, Inc. announced on March 28, 2025, the dismissal of its former auditor, Marcum Asia CPAs LLP. The company has appointed Deloitte & Touche as its succ
Belite Bio Announces 2025 Annual Shareholder Meeting Materials — 6-K · Mar 18, 2025 Risk: low
Belite Bio, Inc. announced on March 18, 2025, that it has made materials available to shareholders in connection with its 2025 annual general meeting. These mat
Belite Bio Reports Q4 & FY 2024 Results — 6-K · Mar 17, 2025 Risk: low
Belite Bio, Inc. announced its fourth quarter and full-year 2024 financial results on March 17, 2025. The company also provided a corporate update alongside the
Belite Bio Files 2024 Annual Report — 20-F · Mar 17, 2025 Risk: medium
Belite Bio, Inc. filed its 20-F annual report for the fiscal year ending December 31, 2024. The company, located at 12750 High Bluff Drive, Suite 475, San Diego
Belite Bio Releases Interim Phase 3 Stargardt Trial Data — 6-K · Feb 27, 2025 Risk: medium
Belite Bio, Inc. announced on February 26, 2025, interim analysis results from its pivotal global Phase 3 DRAGON trial for tinlarebant in adolescent Stargardt d
Belite Bio Prices $1M Direct Offering of ADSs and Warrants — 6-K · Feb 6, 2025 Risk: medium
On February 5, 2025, Belite Bio, Inc. entered into a securities purchase agreement for a registered direct offering of 258,309 American Depositary Shares (ADSs)
Belite Bio Files November 2024 6-K Report — 6-K · Nov 12, 2024 Risk: low
Belite Bio, Inc. filed a Form 6-K on November 12, 2024, reporting for the month of November 2024. The filing is a report of a foreign private issuer pursuant to
Belite Bio Files Form 6-K for November 2024 — 6-K · Nov 4, 2024 Risk: low
On November 3, 2024, Belite Bio, Inc. entered into an inducement offer letter agreement. This filing is a Form 6-K report for the month of November 2024, indica
Belite Bio Appoints New Chief Medical Officer — 6-K · Sep 3, 2024 Risk: low
Belite Bio, Inc. announced on September 1, 2024, the appointment of Dr. Hendrik P. N. Scholl, MD, MA, as its new Chief Medical Officer. This appointment is deta
Belite Bio Files August 2024 6-K Report — 6-K · Aug 9, 2024 Risk: low
Belite Bio, Inc. filed a Form 6-K on August 9, 2024, reporting its activities for the month of August 2024. The filing is a report of a foreign private issuer p
Belite Bio Files 6-K Report — 6-K · May 14, 2024 Risk: low
Belite Bio, Inc. filed a Form 6-K on May 14, 2024, reporting on its activities for the month of May 2024. The filing is a report of a foreign private issuer pur
Belite Bio Prices $3M Direct Offering of ADSs and Warrants — 6-K · Apr 26, 2024 Risk: medium
On April 25, 2024, Belite Bio, Inc. entered into a securities purchase agreement with an institutional investor for a registered direct offering. The company wi
Belite Bio Submits Tinlarebant Trial to Japan's PMDA — 6-K · Mar 22, 2024 Risk: medium
On March 22, 2024, Belite Bio, Inc. announced the submission of its tinlarebant clinical trial application to Japan's Pharmaceuticals and Medical Devices Agency
Belite Bio, Inc. Files 20-F Annual Report for Fiscal Year Ended December 31, 2023 — 20-F · Mar 12, 2024 Risk: medium
BELITE BIO, INC (BLTE) filed a Foreign Annual Report (20-F) with the SEC on March 12, 2024. Belite Bio, Inc. filed its 20-F annual report for the fiscal year en
Lin Bioscience Discloses Significant Stake in Belite Bio — SC 13G · Feb 12, 2024 Risk: low
Lin Bioscience International Ltd. filed an SC 13G on February 12, 2024, disclosing its ownership of Belite Bio, Inc. ordinary shares as of December 31, 2023. Th

Risk Profile

Risk Assessment: Of BLTE's 24 recent filings, 1 were flagged as high-risk, 11 as medium-risk, and 12 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

Hendrik P. N. Scholl, MD, MA

Industry Context

Belite Bio operates in the highly competitive biopharmaceutical sector, focusing on rare genetic eye diseases. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on innovation, clinical trial outcomes, and securing intellectual property.

Top Tags

sec-filing (4) · financing (3) · financial-results (3) · corporate-update (3) · offering (3) · Biotechnology (2) · clinical-trial-results (2) · pharmaceutical (2) · stargardt-disease (2) · 6-K (2)

Key Numbers

Revenue: $0 — For the fiscal year ended December 31, 2025, indicating pre-commercial stage.
Ordinary shares outstanding: 39,339,960 — As of December 31, 2025, representing the company's capital structure.
Par value per ordinary share: US$0.0001 — The nominal value of each ordinary share.
Ordinary Shares: 1,953,124 — Number of shares sold in the PIPE financing
ADSs Offered: 230,770 — Represents the number of American Depositary Shares in the registered direct offering.
Fiscal Year End: 1231 — Indicates the end of the reporting period for the 20-F.
Filing Date: 20250317 — The date the 20-F was officially submitted to the SEC.
Gross Proceeds: $1.0M — Funds raised from the registered direct offering.
ADSs and Warrants: 258,309 — Number of securities sold in the offering.
ADSs and Warrants Offered: 651,380 — Represents the total number of securities being sold in the offering.
Offering Price: $4.60 — The price per unit of one ADS and one accompanying warrant.
Form Type: 20-F — SEC Filing Type
SEC File Number: 001-41359 — SEC Filing Number

Related Companies

BTE

Frequently Asked Questions

What are the latest SEC filings for Belite Bio, INC (BLTE)?

Belite Bio, INC has 27 recent SEC filings from Feb 2024 to Mar 2026, including 23 6-K, 3 20-F, 1 SC 13G. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of BLTE filings?

Across 27 filings, the sentiment breakdown is: 3 bullish, 1 bearish, 23 neutral. The dominant sentiment is neutral.

Where can I find Belite Bio, INC SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Belite Bio, INC (BLTE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Belite Bio, INC?

Financial highlights for Belite Bio, INC are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for BLTE?

The investment thesis for BLTE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Belite Bio, INC?

Key executives identified across Belite Bio, INC's filings include Hendrik P. N. Scholl, MD, MA.

What are the main risk factors for Belite Bio, INC stock?

Of BLTE's 24 assessed filings, 1 were flagged high-risk, 11 medium-risk, and 12 low-risk.

What are recent predictions and forward guidance from Belite Bio, INC?

Forward guidance and predictions for Belite Bio, INC are extracted from SEC filings as they are enriched.